|
515 Companies |
|
302 Products |
|
302 Products |
|
167 Mechanisms of Action |
|
1404 Trials |
|
125634 News |
|
| «12...15151516151715181519152015211522152315241525...15771578» |
- sildenafil / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Phase classification: Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers (clinicaltrials.gov) - Sep 20, 2016
P1b, N=26, Active, not recruiting, Sponsor: Virginia Commonwealth University
Phase classification: P1 --> P1b
- AU-101 / Aurora Biopharma
Trial primary completion date, Metastases: Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma (clinicaltrials.gov) - Sep 19, 2016
P1, N=36, Recruiting, Sponsor: Baylor College of Medicine
Phase classification: P1 --> P1b Trial primary completion date: Jul 2016 --> Jul 2017
- imatinib / Generic mfg.
Trial primary completion date, Stroma: ABILITY: Influence of an Acidic Beverage on the Imatinib Exposure After Major Gastrectomy (clinicaltrials.gov) - Sep 16, 2016
P1, N=12, Recruiting, Sponsor: Radboud University
Trial primary completion date: Jul 2016 --> Jul 2017 Trial primary completion date: Jun 2016 --> Dec 2016
- || Fragmin (dalteparin sodium) / Pfizer, Eisai
Trial primary completion date: Dalteparin in Preventing DVT in Participants With Cancer (clinicaltrials.gov) - Sep 15, 2016
P=N/A, N=70, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jun 2016 --> Dec 2016 Trial primary completion date: Jul 2017 --> Jul 2018
- || Piqray (alpelisib) / Novartis
Trial primary completion date, Combination therapy, Stroma: A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients (clinicaltrials.gov) - Sep 15, 2016
P1, N=56, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jul 2017 --> Jul 2018 Trial primary completion date: Dec 2016 --> Jul 2017
- | amcasertib (BBI-503) / Sumitomo Pharma
Trial initiation date, Trial primary completion date, Stroma, Metastases: A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors (clinicaltrials.gov) - Sep 15, 2016
P2, N=30, Not yet recruiting, Sponsor: Boston Biomedical, Inc
Trial primary completion date: Dec 2016 --> Jul 2017 Initiation date: Jul 2016 --> Jan 2017 | Trial primary completion date: Jul 2017 --> Dec 2018
- New trial, Surgery: Negative Pressure Dressing Therapy in Soft Tissue Sarcoma Surgery (clinicaltrials.gov) - Sep 15, 2016
P=N/A, N=160, Not yet recruiting, Sponsor: NHS Greater Glasgow and Clyde
- Enrollment open, Trial initiation date: DHEA in Synovial Sarcoma Patients (clinicaltrials.gov) - Sep 15, 2016
P1/2, N=47, Recruiting, Sponsor: Washington University School of Medicine
Initiation date: Jul 2016 --> Jan 2017 | Trial primary completion date: Jul 2017 --> Dec 2018 Not yet recruiting --> Recruiting | Initiation date: Jun 2016 --> Sep 2016
- ||| Avastin (bevacizumab) / Roche
Trial initiation date: Optune (clinicaltrials.gov) - Sep 15, 2016
P2, N=85, Not yet recruiting, Sponsor: RTOG Foundation, Inc.
Not yet recruiting --> Recruiting | Initiation date: Jun 2016 --> Sep 2016 Initiation date: Jun 2016 --> Oct 2016
- | sEphB4-HSA / VasGene, National Cancer Institute
Enrollment open: sEphB4-HSA in Treating Patients With Kaposi Sarcoma (clinicaltrials.gov) - Sep 15, 2016
P2, N=42, Recruiting, Sponsor: AIDS Malignancy Consortium
Initiation date: Jun 2016 --> Oct 2016 Suspended --> Recruiting
- mipetresgene autoleucel (TBI-1301) / Takara
Enrollment open: Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors (clinicaltrials.gov) - Sep 14, 2016
P1, N=15, Recruiting, Sponsor: University Health Network, Toronto
Suspended --> Recruiting Not yet recruiting --> Recruiting
- New trial: Transcutaneous Oxygen as a Predictor of Wound Healing Complications in Preoperatively Radiated Soft Tissue Sarcoma (clinicaltrials.gov) - Sep 13, 2016
P=N/A, N=60, Recruiting, Sponsor: Loyola University
- | Orpathys (savolitinib) / AstraZeneca, Hutchmed
New P2 trial, Metastases: A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer (clinicaltrials.gov) - Sep 13, 2016
P2, N=45, Not yet recruiting, Sponsor: Hutchison Medipharma Limited
- ||| Ibrance (palbociclib) / Pfizer
New P1 trial, Combination therapy, Metastases: Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors (clinicaltrials.gov) - Sep 13, 2016
P1, N=90, Not yet recruiting, Sponsor: Emory University
- imatinib / Generic mfg.
Trial primary completion date: Basket 1: Imatinib in Patients With Desmoid Tumor and Chondrosarcoma (clinicaltrials.gov) - Sep 12, 2016
P2, N=35, Active, not recruiting, Sponsor: Italian Sarcoma Group
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2016 --> Dec 2016
- || imatinib / Generic mfg.
Trial primary completion date: Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator (clinicaltrials.gov) - Sep 12, 2016
P4, N=152, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Aug 2016 --> Dec 2016 Trial primary completion date: Oct 2024 --> Jun 2024
- || Trial primary completion date, IO biomarker: Molecular-Guided Therapy for Childhood Cancer (clinicaltrials.gov) - Sep 9, 2016
P=N/A, N=56, Recruiting, Sponsor: Giselle Sholler
Trial primary completion date: Oct 2024 --> Jun 2024 Trial primary completion date: Jun 2016 --> Jun 2018
- Enrollment open, Trial initiation date: Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort (clinicaltrials.gov) - Sep 9, 2016
P2, N=51, Recruiting, Sponsor: Jonsson Comprehensive Cancer Center
Trial primary completion date: Jun 2016 --> Jun 2018 Not yet recruiting --> Recruiting | Initiation date: Jun 2016 --> Feb 2016
- Trial primary completion date: Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors (clinicaltrials.gov) - Sep 8, 2016
P=N/A, N=30, Suspended, Sponsor: O'Dorisio, M S
Not yet recruiting --> Recruiting | Initiation date: Jun 2016 --> Feb 2016 Trial primary completion date: Jul 2016 --> Dec 2018
- New trial, Surgery: Supervised Exercise in Improving Physical Fitness Before Surgery in Patients With Resectable Bone Cancer (clinicaltrials.gov) - Sep 8, 2016
P=N/A, N=30, Recruiting, Sponsor: M.D. Anderson Cancer Center
- Trial completion: Evaluating Bacterial Response in Sarcoma Management Using Fluorescence Imaging (clinicaltrials.gov) - Sep 7, 2016
P=N/A, N=20, Completed, Sponsor: University Health Network, Toronto
Trial primary completion date: Jul 2016 --> Dec 2018 Active, not recruiting --> Completed
- ||| ontorpacept intratumoral (TTI 621 intratumoral) / Pfizer
New P1 trial: Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides (clinicaltrials.gov) - Sep 7, 2016
P1, N=54, Not yet recruiting, Sponsor: Trillium Therapeutics Inc.
- Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
New P1 trial, Combination therapy: Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 (clinicaltrials.gov) - Sep 7, 2016
P1, N=27, Not yet recruiting, Sponsor: David Wald
- ||| Trial completion, Enrollment change: FORTO: A Retrospective Non-intervention Study to Characterize FOlate Rescue Treatment in Osteosarcoma Patients Treated With HDMTX (clinicaltrials.gov) - Sep 6, 2016
P=N/A, N=116, Completed, Sponsor: Isofol Medical AB
Active, not recruiting --> Completed Recruiting --> Completed | N=150 --> 116
- |||| Enrollment open, Surgery: Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord (clinicaltrials.gov) - Sep 6, 2016
P2, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed | N=150 --> 116 Not yet recruiting --> Recruiting
- Keytruda (pembrolizumab) / Merck (MSD)
New P1/2 trial, Combination therapy, PD(L)-1 Biomarker, Surgery, Metastases: Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Sep 6, 2016
P1/2, N=47, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Research Center
- Stivarga (regorafenib) / Bayer, sunitinib / Generic mfg.
New P2 trial, Stroma: Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTs (clinicaltrials.gov) - Sep 5, 2016
P2, N=25, Not yet recruiting, Sponsor: Asan Medical Center
- Enrollment change, Trial primary completion date: Proton RT for the Treatment of Pediatric Rhabdomyosarcoma (clinicaltrials.gov) - Sep 3, 2016
P2, N=110, Recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting N=80 --> 110 | Trial primary completion date: Jun 2016 --> Jun 2020
- Enrollment closed: Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas (clinicaltrials.gov) - Sep 3, 2016
P2, N=70, Active, not recruiting, Sponsor: Massachusetts General Hospital
N=80 --> 110 | Trial primary completion date: Jun 2016 --> Jun 2020 Recruiting --> Active, not recruiting
- || Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
Preclinical, Trial primary completion date, Metastases: A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma (clinicaltrials.gov) - Sep 2, 2016
P2, N=208, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2019 --> Oct 2020
- Enrollment closed, Enrollment change, Trial primary completion date: Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis (clinicaltrials.gov) - Sep 1, 2016
P1, N=4, Active, not recruiting, Sponsor: Kathy Miller
Trial primary completion date: Feb 2019 --> Oct 2020 Recruiting --> Active, not recruiting | N=15 --> 4 | Trial primary completion date: Apr 2017 --> Oct 2016
- Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Trial primary completion date: ISG-STS-1001: Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy (clinicaltrials.gov) - Aug 31, 2016
P3, N=350, Recruiting, Sponsor: Italian Sarcoma Group
Recruiting --> Active, not recruiting | N=15 --> 4 | Trial primary completion date: Apr 2017 --> Oct 2016 Trial primary completion date: Jun 2016 --> Jan 2018
- ||| Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Enrollment change, Trial primary completion date: ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM) (clinicaltrials.gov) - Aug 31, 2016
P2, N=141, Recruiting, Sponsor: Mario Negri Institute for Pharmacological Research
Trial primary completion date: Jun 2016 --> Jan 2018 N=79 --> 141 | Trial primary completion date: Oct 2015 --> Oct 2016
- Crixivan (indinavir sulfate) / Merck (MSD)
Trial completion, Combination therapy, IO biomarker, Metastases: Treatment With Indinavir and Chemotherapy for Advanced Classical Kaposi's Sarcoma (clinicaltrials.gov) - Aug 30, 2016
P2, N=25, Completed, Sponsor: Barbara Ensoli, MD, PhD
N=79 --> 141 | Trial primary completion date: Oct 2015 --> Oct 2016 Active, not recruiting --> Completed
- imatinib / Generic mfg.
Trial completion, Surgery: Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis (clinicaltrials.gov) - Aug 30, 2016
P1/2, N=40, Completed, Sponsor: UNICANCER
Active, not recruiting --> Completed Recruiting --> Completed
- docetaxel / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Metastases: Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma (clinicaltrials.gov) - Aug 30, 2016
P2, N=90, Completed, Sponsor: UNICANCER
Recruiting --> Completed Recruiting --> Completed
- paclitaxel / Generic mfg.
Trial completion, Surgery, Metastases: Paclitaxel in Treating Patients With Locally Advanced or Metastatic Soft Tissue Angiosarcoma or Lymphangiosarcoma That Cannot Be Removed By Surgery (clinicaltrials.gov) - Aug 30, 2016
P2, N=30, Completed, Sponsor: UNICANCER
Recruiting --> Completed Recruiting --> Completed
- Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Trial primary completion date: Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors (clinicaltrials.gov) - Aug 30, 2016
P1, N=30, Recruiting, Sponsor: Merrimack Pharmaceuticals
Recruiting --> Completed Trial primary completion date: Dec 2015 --> Dec 2016
- ||| Opdivo (nivolumab) / BMS
Enrollment open, Trial initiation date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker: Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18) (clinicaltrials.gov) - Aug 30, 2016
P1, N=68, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Dec 2015 --> Dec 2016 Not yet recruiting --> Recruiting | Initiation date: Mar 2016 --> Aug 2016 | Trial primary completion date: Mar 2018 --> Aug 2018
- New P4 trial: Feasibility and Yield of a New 20 G ProCore Needle With Coiled Sheath in the Gastrointestinal Subepithelial Tumors (clinicaltrials.gov) - Aug 29, 2016
P4, N=38, Enrolling by invitation, Sponsor: Pusan National University Hospital
- Biomarker, Enrollment closed, Enrollment change: Retinoblastoma Biomarker Study (clinicaltrials.gov) - Aug 29, 2016
P=N/A, N=1995, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Initiation date: Mar 2016 --> Aug 2016 | Trial primary completion date: Mar 2018 --> Aug 2018 Completed --> Active, not recruiting | N=700 --> 1995
- H1299 cell lysate with iscomatrix adjuvant vaccine / National Cancer Institute
Enrollment change, IO biomarker: Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum (clinicaltrials.gov) - Aug 29, 2016
P1/2, N=21, Suspended, Sponsor: National Cancer Institute (NCI)
Completed --> Active, not recruiting | N=700 --> 1995 N=60 --> 21
- |||||| crenolanib (ARO-002) / AROG
Enrollment open, Stroma, Metastases: Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST (clinicaltrials.gov) - Aug 26, 2016
P3, N=120, Recruiting, Sponsor: Arog Pharmaceuticals, Inc.
N=60 --> 21 Not yet recruiting --> Recruiting
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2 trial, Monotherapy, Tumor mutational burden, PD(L)-1 Biomarker, Surgery, Stroma, Metastases: NCI-2016-01004: Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Aug 25, 2016
P2, N=40, Not yet recruiting, Sponsor: Jonsson Comprehensive Cancer Center
- | New P2 trial, Metastases: Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone (clinicaltrials.gov) - Aug 25, 2016
P2, N=100, Not yet recruiting, Sponsor: Dana-Farber Cancer Institute
- || Lartruvo (olaratumab) / Eli Lilly
Trial primary completion date, Metastases: ANNOUNCE 2: A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Aug 25, 2016
P1b, N=196, Recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Trial primary completion date: Nov 2019 --> Jul 2019
- ||||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
New P2 trial, Metastases: Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours (clinicaltrials.gov) - Aug 25, 2016
P2, N=160, Not yet recruiting, Sponsor: Canadian Cancer Trials Group
- CMB305 / Merck (MSD)
Phase classification, Metastases: Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 (clinicaltrials.gov) - Aug 24, 2016
P1b, N=45, Recruiting, Sponsor: Immune Design
Trial primary completion date: Nov 2019 --> Jul 2019 Phase classification: P1 --> P1b
- mocetinostat (MGCD0103) / Otsuka, BMS
Enrollment closed, Enrollment change, Metastases: SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma (clinicaltrials.gov) - Aug 24, 2016
P2, N=20, Active, not recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
Phase classification: P1 --> P1b Recruiting --> Active, not recruiting | N=40 --> 20
- New trial, Stroma: SARCO-GIST: Sarcopenia in Patients With Gastrointestinal Stromal Tumours (clinicaltrials.gov) - Aug 23, 2016
P=N/A, N=31, Completed, Sponsor: CHU de Reims